12:00 AM
May 12, 2003
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OvaRex MAb: Phase II comparability data; Phase III

In a U.S. Phase II study in 26 patients, OvaRex derived from mouse ascites fluid showed no significant pharmacokinetic, immunologic or safety differences compared to OvaRex manufactured using a protein-free cell culture process. Twelve...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >